A share price of Tarsus Pharmaceuticals Inc [TARS] is currently trading at $40.58, down -2.29%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TARS shares have gain 2.24% over the last week, with a monthly amount drifted -0.90%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On November 20, 2023, Goldman initiated with a Neutral rating and assigned a price target of $19 on the stock. William Blair started tracking the stock assigning a Outperform rating and suggested a price target of $44 on July 18, 2023. Guggenheim initiated its recommendation with a Buy. Barclays started tracking with a Overweight rating for this stock on August 01, 2022, and assigned it a price target of $40. In a note dated December 21, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $40 on this stock.
Tarsus Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $20.08 and $57.28. Currently, Wall Street analysts expect the stock to reach $69 within the next 12 months. Tarsus Pharmaceuticals Inc [NASDAQ: TARS] shares were valued at $40.58 at the most recent close of the market. An investor can expect a potential return of 70.03% based on the average TARS price forecast.
Analyzing the TARS fundamentals
Trailing Twelve Months sales for Tarsus Pharmaceuticals Inc [NASDAQ:TARS] were 233.67M which represents 183.68% growth. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.47%, Pretax Profit Margin comes in at -0.45%, and Net Profit Margin reading is -0.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.4 and Total Capital is -0.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 39.95 points at the first support level, and at 39.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.39, and for the 2nd resistance point, it is at 42.21.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Tarsus Pharmaceuticals Inc [NASDAQ:TARS] is 5.57. Further, the Quick Ratio stands at 5.54, while the Cash Ratio is 2.04. Considering the valuation of this stock, the price to sales ratio is 7.30, the price to book ratio is 4.98.
Transactions by insiders
Recent insider trading involved Farrow Jeffrey S,, that happened on Jun 17 ’25 when 13608.0 shares were sold. Officer, Farrow Jeffrey S completed a deal on Jun 17 ’25 to buy 13608.0 shares. Meanwhile, Chief Medical Officer Lin Elizabeth Yeu sold 1006.0 shares on Jun 16 ’25.
